

# Association between inflammatory indexes and erectile dysfunction in U.S. adults: National Health and Nutrition Examination Survey 2001-2004

Chunhui Liu, PhD<sup>1</sup>, Yue Gao, MD<sup>2</sup>, Jie Ji, MD<sup>2</sup>, Chao Sun, PhD<sup>1,\*</sup>, Ming Chen, PhD<sup>1,\*</sup>

<sup>1</sup>Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China

<sup>2</sup>Surgical Research Center, Institute of Urology, Medical School of Southeast University, Nanjing, 210009, China

\*Corresponding author: Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China. Email: 101011756@seu.edu.cn; Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China. Email: 101011118@seu.edu.cn

# Abstract

Background: The association of inflammatory biomarkers with erectile dysfunction (ED) is still largely unknown.

Aim: The study sought to explore the association of inflammatory biomarkers with ED in U.S. adults.

**Methods:** Participant data for this study were extracted from the National Health and Nutrition Examination Survey, and individuals that lacked information on clinical variables were excluded. Dose-response curve analysis was applied to explore the association of inflammatory biomarkers with ED prevalence. The confounders were adjusted for with weighted logistic regression analysis. We employed 1:1 propensity score matching to eliminate the effects of clinical variables to confirm the reliability of the results.

**Outcomes:** ED prevalence was investigated with potential risk factors.

**Results:** A total of 2331 men  $\geq$ 20 years of age who participated in the National Health and Nutrition Examination Survey 2001-2004 were included in this study. Compared with individuals without ED, ED cohort displayed higher levels of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammatory index, and systemic inflammation response index. Dose-response curve analysis indicated ED prevalence increased with the increase of platelet-to-lymphocyte ratio, systemic immune-inflammatory index, and systemic inflammation response index. Weighed logistic regression analysis revealed neutrophil-to-lymphocyte ratio was positively associated with ED. The reliability of the results was confirmed by 1:1 propensity score matching reanalysis.

Clinical Implications: Individuals with chronic inflammatory conditions should be alert for the development of ED.

**Strengths and Limitations:** It is a large controlled study to investigate the relationship between inflammatory indexes and ED. However, it is a cross-sectional study and it lacks an accurate assessment of the degree of ED.

Conclusion: Inflammatory biomarkers were associated with ED prevalence.

Keywords: NLR; PLR; LMR; erectile dysfunction.

# Introduction

Erectile dysfunction (ED) refers to the inability to achieve or maintain an erection satisfactory for sexual intercourse and is a common clinical entity that seriously influences people's quality of life and physical and mental health.<sup>1</sup> An estimated 50% of men 40 to 70 years of age experience ED, with almost 15% of patients reporting complete ED and the remainder reporting varying degrees of ED.<sup>2</sup> Conditions commonly associated with ED include aging, depression, obesity, physical inactivity, diabetes, hypertension, dyslipidemia, cardiovascular disease, lower urinary tract symptoms associated with benign prostatic hyperplasia, hypogonadism, and hyperprolactinemia.<sup>3</sup>

Chronic inflammation is considered a common pathophysiologic process and significantly contributes to the emergence and development of ED.<sup>4,5</sup> Patients with ED have high levels of inflammatory markers, including C-reactive protein, interleukins, and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ).<sup>4,6–8</sup> Neutrophil-to-lymphocyte ratio (NLR),<sup>9</sup> platelet-to-lymphocyte ratio (PLR),<sup>10</sup> lymphocyte-to-monocyte ratio (LMR),<sup>11</sup> systemic immune-inflammatory index (SII), and systemic inflammation response index (SIRI)<sup>12</sup> are important indicators of the systemic inflammatory response of the

organism. Due to their easy availability and high sensitivity, they have been proposed as predictors of the prognosis of several diseases. Some of these indicators have been reported to relate to ED. However, most studies have limited number of participants. The relationship between inflammatory indicators and ED is need to explore and validate in larger study cohorts. The National Health and Nutrition Examination Survey (NHANES) is a national survey that monitors the health and nutritional status of adults and children across the United States. From 2001 to 2004, NHANES implemented a question to collect the erectile function of men. A total of 21161 men participated in the survey. In this study, we investigated whether NLR, PLR, MLR, SII, and SIRI are associated with ED and explored potential nonlinear relationships between them using data from the 2001-2004 NHANES.

# Methods

# Data sources

Data for this study were obtained from the NHANES database, with data released publicly on a 2-year cycle. The survey included sociodemographic characteristics,

Received: April 18, 2023. Revised: July 10, 2023. Accepted: July 11, 2023

<sup>©</sup> The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/lice nses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com



Figure 1. Schematic flow diagram of inclusion and exclusion criteria for our study cohort.

physiological indicators, indicators of nutritional status, laboratory tests, and health status. All data are obtained from surveys conducted by experienced medical personnel. A detailed statement of the NHANES database is available on the official website of National Center for Health Statistics (NCHS) (https://www.cdc.gov/nchs/nhanes). All procedures were approved by the NCHS Research Ethics Committee (NCHS IRB/ERB Protocol No. #2011-17), and all participants provided written informed consent. We conformed to the NHANES data user agreement and used the data for secondary analysis. Hence, the ethical review was exempted by the Ethics Committee of the Affiliated Zhongda Hospital of Southeast University.

### **Study population**

A total of 21 161 men participated in the 2001-2004 survey. Individuals without relevant data were excluded. The exclusion criteria and flow were shown in Figure 1. Finally, 2331 men  $\geq$ 20 years of age were included in this study.

#### **Study covariables**

The following variables were included in the study: (1) demographic information, including age, race (Mexican American, non-Hispanic White, non-Hispanic Black, and other), education (less than high school, high school diploma, and more than high school), smoking status (yes or no), and body mass index (BMI) ( $<25.0 \text{ kg/m}^2$ , 25-29.99 kg/m<sup>2</sup>, and  $\geq$ 30.0 kg/m<sup>2</sup>); (2) laboratory data, including platelet count (PC), neutrophil count (NC), lymphocyte count (LC), and monocyte count (MC); (3) questionnaire information, including history of hypertension and diabetes; and (4) physical activity data.

# **ED** assessment

The endpoint of the study was a history of ED. Trained interviewers used the question, "How would you describe your ability to get and keep an erection adequate for satisfactory sexual intercourse" to assess the respondent's erectile function. In this study, "sometimes able or never able" is defined as having ED and "always able or almost always able and usually able" is defined as not having ED, which is consistent with previous studies.<sup>13</sup>

#### **Definition of inflammatory biomarkers**

All indexes are calculated from the results of the complete blood count test and the laboratory methods for the complete blood count test are available on the NHANES website. In addition, LC, MC, PC, and NC were measured in units of 1000 cells/ $\mu$ L. Relevant formulas are as follows: LMR = LC/MC; NLR = NC/LC; PLR = PC/LC; SII = (PC × NC)/LC; SIRI = (NC × MC)/LC.

#### Statistical analysis

In descriptive analysis, continuous variables conforming to a normal distribution were expressed as mean  $\pm$  SD; categorical variables were expressed as frequency and percentage. The t test and chi-square test were used to test the statistical differences between normally distributed continuous and categorical variables in the 2 groups. Because of the multistage and probability cluster design of NHANES, we considered weights in this study to improve the representativeness. Weighted multivariable-adjusted logistic regression was used to calculate the odds ratio with 95% confidence interval (CI). Three models were built to assess the association between inflammatory biomarkers and ED. Model 1 is unadjusted. In model 2, we adjusted for age, race, BMI, smoking, education, and poverty impact ratio (PIR). Finally, we adjusted for model 2 covariates and for physical activity, hypertension, diabetes, and glomerular filtration rate (GFR) in model 3.

The restricted cubic spline function was applied to describe the dose-response relationship between the inflammatory biomarkers and ED, adjusted for variables including age, race, smoking status, education status, PIR, physical activity status, hypertension, diabetes, and GFR.

Propensity score matching (PSM) was used to reduce the effects of data bias and confounding variables for a more reliable result. PSM involves matching study subjects with similar propensity scores across treatment groups, which ensures study objectivity and uses similar covariate distributions to construct the study population without impacting study outcomes, which is equivalent to achieving randomization. In this study, the Matching package of R (version 3.5.1; R Foundation for Statistical Computing) was used to obtain the control population by matching the ED patient data separately at a 1:1 matching ratio.

All statistical analyses were performed using R (version 3.5.1). P < .05 (2-sided) was considered statistically significant.

#### Results

A total of 21 161 (weighted N = 46 116 226) participants in the NHANES pool from 2001 to 2004 were used as subjects for this study. Figure 1 shows the flow chart. We first excluded women (n = 10 860) and men younger than 20 years of age (n = 5347). Subsequent exclusion criteria were as follows: (1) participants who had not completed the ED survey (n = 838); (2) missing BMI, PIR, education status, smoking status, hypertension, diabetes, prostate cancer (Pca) status, and activity data (n = 388); and (3) missing data for calculating inflammation biomarker (n = 1397). Finally, a total of 2331 participants Table 1. Baseline demographic and clinical characteristics of study population, National Health and Nutrition Examination Survey 2001-2004.

Characteristic	Non-ED (n = 33 206 622)	ED (n = 12 909 604)	P value	
Age. v	$51.28 \pm 9.40$	$64.36 \pm 11.46$	<.001ª	
Race			<.001 <sup>a</sup>	
Mexican American	1688879 (5.09)	527 722.7 (4.09)		
Non-Hispanic White	26 590 303 (80.08)	10 513 627.8 (81.44)		
Non-Hispanic Black	2849800(8.58)	1 015 232.3 (7.86)		
Other	2077640 (6.26)	853 020.8 (6.61)		
PIR			<.001 <sup>a</sup>	
<1.3	3957792 (11.92)	2 120 369 (16.42)		
>1.3, <3.5	9 578 620 (28.85)	5 331 204 (41.30)		
>3.5	19670209 (59.24)	5 458 030 (42.28)		
Education			<.001 <sup>a</sup>	
Less than high school	3742213 (11.27)	3 388 983 (26.25)		
High school diploma	8 984 646 (27.06)	3 126 972 (24.22)		
More than high school	20 479 763 (61.67)	6 393 649 (49.53)		
Cigarette smoking			<.001ª	
Yes	19675013(59.25)	9 103 022 (70.51)		
No	13 531 609 (49.75)	3 806 582 (29.49)		
BMI			<.001ª	
$< 2.5 \text{ kg/m}^2$	7462771 (22.47)	3007015(23.29)		
$2.5-30 \text{ kg/m}^2$	15602551 (46.99)	5093350(39.45)		
$>30 \text{ kg/m}^2$	10141300(3054)	4 809 238 (37 25)		
Hypertension	10111300 (30.34)	1007 230 (37.23)	< 001 <sup>a</sup>	
Yes	9827007(2959)	6742 303 (52 23)		
No	23 379 614 (70 41)	6167300 (4777)		
Diabetes	23 37 7 011 (70.11)	010/ 300 (1/.//)	< 001 <sup>a</sup>	
Yes	1 815 550 3 (5 47)	2 892 556 8 (22 41)		
No	31 002 017 1 (93 36)	9 841 821 6 (76 24)		
Prediabetes	389 054 2 (1 17)	175 225 1 (1 36)		
Physical activity status	303 03 1.2 (1.17)	175 225.1 (1.50)		
Vigorous			<.001 <sup>a</sup>	
Yes	12,491,628 (37,62)	2 382 143 (18.45)		
No	20 714 994 (62.38)	10 527 460 (81,55)		
Moderate		1002/ 100 (01100)	<.001 <sup>a</sup>	
Yes	19293274 (58.1)	6494614(50.31)		
No	13 913 348 (41.9)	6 414 989 (49.69)		
GFR, mL/(min* $1.73m^2$ )	$98.26 \pm 18.34$	86.48+ 20.83	<.001 <sup>a</sup>	
Platelet count $10^3/\mu$ I	$254.06 \pm 60.36$	240.24 + 66.04	< 001 <sup>a</sup>	
Neutrophil count $10^3/\mu I$	$4 16 \pm 158$	4 33 + 1 50	017 <sup>a</sup>	
I umphosite count, $10^{3}/\mu$	$4.10 \pm 1.50$ 2.09 $\pm$ 1.54	$4.55 \pm 1.50$	.017	
Monocyte count, 10 $\mu$ L	$2.09 \pm 1.34$	$2.00 \pm 2.33$	.347	
Subscripting $10^{-7}\mu$ L	$0.37 \pm 0.19$	$0.01 \pm 0.22$	.023	
511, × 10°	$338.37 \pm 302.63$	$630.87 \pm 4/7.74$	<.001	
INLK DI D	$2.19 \pm 1.00$ 125 71 + 50 20	$2.61 \pm 1.43$	<.001"	
rlr I MD	$133./1 \pm 30.28$	$143.21 \pm 63.67$ 2.27 + 1.55	.062	
	$5.01 \pm 1.30$ $10.08 \pm 6.44$	$3.3/\pm 1.33$ 11.99 $\pm$ 9.02	<.001*	
	10.00 ± 0.44	11.00 ± 2.02	<.001"	

Values are mean  $\pm$  SD or n (%). For categorical variables, *P* values were analyzed by chi-square tests. For continuous variables, *P* values were analyzed by *t* test. All of the continuous variables were exhibited by mean and SD. Abbreviations: BMI, body mass index; ED, erectile dysfunction; GFR, glomerular filtration rate; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PIR, poverty impact ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammatory index; SIRI, systemic inflammation response index. <sup>a</sup>Statistical difference.

were enrolled in this research, of whom 898 were experiencing ED.

The differences between participants with and without ED are presented In Table 1. We found that age (P < .001), race (P < .001), PIR (P < .001), education status (P < .001), cigarette smoking (P < .001), BMI (P < .001), hypertension (P < .001), diabetes (P < .001), physical activity status (P < .001), and GFR (P < .001) were differed statistically. Compared with individuals without ED, those with ED had higher SII (P < .001), NLR (P < .001), SIRI (P < .001), and LMR (P < .001).

The dose-response curve revealed that the ED prevalence increased with the increase of PLR, SII, and SIRI after adjusting for age, race, smoking, education status, PIR, physical activity, hypertension, diabetes, and GFR (Figure 2). Interestingly, curves of LMR and NLR had an inflection point. For people with NLR >2, the higher the NLR was, the greater the risk of suffering from ED was.

The association between inflammatory indexes and ED was assessed by weighted logistic regression. We found that NLR was an independent risk factor for ED in models 1 (adjusted odds ratio [aOR], 1.36; 95% CI; 1.25-1.48; P < .001), 2 (aOR, 1.14; 95% CI; 1.03-1.27; P = .018), and 3 (aOR, 1.12; 95% CI; 1.01-1.24; P = .031) (Table 2).

PSM analysis was performed on participants to eliminate the effects of confounding factors that may have an impact on ED. The 1:1 PSM analysis was conducted by adjusting



Adjusted to:Age=59 Race=3 smoke=1 EDU=3 PIR=3 vigorous\_activity=2 moderate\_activity=2 HBP=2 DM=2 GFR=89.86

Figure 2. The dose-response analysis of inflammatory biomarkers and erectile dysfunction before propensity score matching.

Table 2. Prevalence ratios of prevalent erectile dysfunction by inflammatory biomarkers, National Health and Nutrition Examination Survey 2001-2004.

	Model 1 <sup>a</sup>		Model 2 <sup>b</sup>		Model 3 <sup>c</sup>	
	aOR (95% CI)	Р	aOR (95% CI)	Р	aOR (95% CI)	Р
SII	1.00 (1.00, 1.00)	<.001 <sup>d</sup>	1.00 (1.00, 1.00)	.174	1.00 (1.00, 1.00)	.214
NLR	1.36 (1.25, 1.48)	<.001 <sup>d</sup>	1.14 (1.03, 1.27)	.018 <sup>d</sup>	1.12 (1.01, 1.24)	.031 <sup>d</sup>
PLR	1.00 (1.00, 1.00)	.038 <sup>d</sup>	1.00(1.00, 1.00)	.402	1.00(1.00, 1.00)	0.322
LMR	0.79 (0.71, 0.87)	<.001 <sup>d</sup>	0.93 (0.85, 1.02)	.137	0.94 (0.86, 1.03)	.175
SIRI	1.04 (1.02, 1.05)	<.001 <sup>d</sup>	1.01 (0.99, 1.03)	.236	1.01 (0.99, 1.02)	.501

Abbreviations: aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-tolymphocyte ratio; PIR, poverty impact ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammatory index; SIRI, systemic inflammation response index. <sup>a</sup>Model 1 is unadjusted. <sup>b</sup>Model 2 adjusted for age, race, BMI, smoking, education, and PIR. <sup>c</sup>Model 3 adjusted for model 2 covariates and for hypertension, diabetes, and glomerular filtration rate. <sup>d</sup>Statistical difference.

for variables in Figure 3. A total of 543 individuals with ED and 543 individuals without ED were matched. Baseline features of the study population after PSM are described in Table 3. Age, race, PIR, education status, smoking status, BMI, hypertension, diabetes, physical activity status, and GFR did not significantly differ between the 2 cohorts. Moreover, we discovered that compared with non-ED cohort, the ED cohort displayed higher levels of NLR and PLR and a lower level of LMR.

After adjusting for age, race, smoking status, education status, PIR, physical activity status, hypertension, diabetes, and GFR, the dose-response curve showed that ED prevalence was positively related to PLR, SII, and SIRI and was negatively related to LMR. Similarly, ED risk increases with the increase of NLR for those with NLR >2 (Figure 4). In addition, multivariate logistic regression was also performed after PSM. It showed that NLR (model 1: aOR, 1.1; 95% CI, 1-1.21; *P* = .049; model 2: aOR, 1.1; 95% CI, 1-1.23; *P* = .034), PLR (model 1: aOR, 1; 95% CI, 1.01-1.23; *P* = .034), PLR (model 1: aOR, 1; 95% CI, 1-1; *P* = .038; model 2: aOR, 1; 95% CI, 1-1;

P = .04; model 3: aOR, 1; 95% CI, 1-1; P = .035), and LMR (model 1: aOR, 0.91; 95% CI, 0.84-0.97; P = .01; model 2: aOR, 0.9; 95% CI, 0.83-0.97; P = .008; model 3: aOR, 0.9; 95% CI, 0.83-0.97; P = .007) were independent risk factors in all 3 models (Table 4).

# Discussion

Our research investigated the association of inflammatory biomarkers and ED prevalence based on the cumulative NHANES dataset. The NHANES sample population is representative of the U.S. population. It is one of the largest databases available for inflammatory biomarkers and ED in the general population. To the best of our knowledge, this is the first study to explore the connection between ED prevalence and NLR, PLR, LMR, SII, or SIRI.

Inflammation is considered to be one of the triggers of ED, and studies have found enhanced levels of inflammatory factors such as interleukin (IL)-6, IL-1 $\beta$ , and TNF- $\alpha$  in ED patients and rats.<sup>14</sup> Araña Rosaínz et al<sup>15</sup> verified that the



Figure 3. Propensity score matching analysis was performed by the 1:1-based minimum adjacency method.

elevation of anti-inflammatory factor IL-10 is related to a reduced risk of ED in diabetic patients. All evidence implies that systemic inflammation is inextricably linked to the development of ED. A large body of evidence suggests that some inflammatory molecules may be of great value in assessing ED risk or treatment efficacy. Several reports have shown that both ED and its severity are associated with mediators and markers of subclinical inflammation and endothelial dysfunction.<sup>16</sup> In addition, 5-item International Index of Erectile Function scores were negatively associated with levels of fibrinogen, IL-1 $\beta$ , vascular hemophilia factor, and IL-6.<sup>17</sup> Although the exact mechanism by which inflammation causes ED is still unclear, it is undeniable that there is a strong link between the two. In the predominantly proinflammatory environment, nitric oxide bioavailability is reduced and vasodilation is impaired due to inhibition of endothelial nitric oxide synthase expression and overproduction of reactive oxygen species, ultimately leading to endothelial dysfunction (Figure 5). $^{18}$ 

NLR is a widely used prognostic index for oncological, cardiovascular, and inflammatory diseases. Neutrophils produce and secrete several inflammatory mediators such as myeloperoxidase (MPO) and reactive oxygen species, which can lead to endothelial cell damage.<sup>19</sup> Liao et al<sup>20</sup> proposed that an NLR over 1.94 predicted ED with a sensitivity of 60.2% and specificity of 76.9%. A meta-analysis demonstrated that ED patients displayed a higher NLR, which is consistent with our findings.<sup>21</sup> In addition, tadalafil reduces systemic inflammation as evidenced by a reduction in inflammatory biomarkers such as NLR and PLR.<sup>22</sup> PLR has been used in a variety of diseases to predict inflammation and mortality because of its easy availability and low cost.<sup>23</sup> An elevated pretreatment PLR predicts a shorter overall survival for patients with prostate cancer.<sup>24</sup> In addition, PLR can be employed as a prognostic marker to assess treatment response in patients with Crohn's disease.<sup>25</sup> PLR can evaluate the risk of systemic inflammatory response syndrome after percutaneous nephrolithotomy and with high sensitivity and specificity.<sup>26</sup> A retrospective study revealed that PLR was associated with severity of ED based on the 5item International Index of Erectile Function. However, only 175 ED patients were included in this study, and the patients were relatively young.<sup>27</sup> In contrast, our study included a much larger number and a wider age range, and the findings were more reliable and generalizable.

LMR has been explored in multiple studies. Low LMR is related to poor prognosis in patients with non-small cell lung cancer.<sup>28</sup> Several studies suggest that the decrease in LMR was related to the release of proinflammatory factors, including IL-6, IL-1 $\beta$ , and TNF- $\alpha$ , which play a vital role in inflammation.<sup>29</sup> However, the association between LMR and ED has not been elaborated. Our results indicated LMR level was an independent risk factor for ED risk, and lower LMR level was related to higher ED risk independent of age, race, and other factors.

The current availability of blood cell testing is very convenient and thus may expand the range of indications for evaluating potential risk of ED in healthy individuals. This research indicated that some inflammatory indicators may help us to evaluate the general risk profile of patients

Table 3. Baseline demographic and clinical characteristics of the study population, National Health and Nutrition Examination Survey 2001-2004.

Characteristic	Non-ED $(n = 543)$	ED $(n = 543)$	P value	
Age, y	$63.93 \pm 10.94$	$64.11 \pm 11.11$	.792	
Race			.515	
Mexican American	91 (16.8)	88 (16.2)		
Non-Hispanic White	342 (63.0)	325 (59.9)		
Non-Hispanic Black	78 (14.4)	95 (17.5)		
Other	32 (5.9)	35 (6.4)		
PIR			.614	
<1.3	119 (21.9)	132 (24.3)		
≥1.3, <3.5	211 (38.9)	209 (38.5)		
≥3.5	213 (39.2)	202 (37.2)		
Education			.416	
Less than high school	167 (30.8)	187 (34.4)		
High school diploma	123 (22.7)	113 (20.8)		
More than high school	253 (46.6)	243 (44.8)		
Cigarette smoking			.742	
Yes	379 (69.8)	373 (68.7)		
No	164 (30.2)	170 (31.3)		
BMI			.781	
$< 2.5 \text{ kg/m}^2$	126 (23.2)	135 (24.9)		
$25-30 \text{ kg/m}^2$	236(43.5)	235(43.3)		
$> 30 \text{ kg/m}^2$	181 (33 3)	173(31.9)		
Hypertension	101 (55.5)	175 (51.9)	466	
Yes	267 (49 1)	254 (46.8)	.100	
No	276 (50.8)	289 (53.2)		
Diabetes	270 (30.0)	207 (33.2)	77	
Yes	92 (16 9)	90 (16 6)	•//	
No	$\frac{1}{2}$ (10.2)	445 (82.0)		
Prediabetec	11 (2 0)	8 (1 5)		
Dhysical activity status	11 (2:0)	8 (1.5)		
Vigorous			655	
Vigorous	111(20.4)	118 (21 7)	.055	
No	(20.7)	(21.7) (25.78.3)		
Moderate	432 (79:0)	423 (78.3)	274	
Voc	267(49.1)	248 (45 7)	.2/4	
ICS No	267(49.1) 276(50.8)	240(43.7) 295(54.2)		
$CEP = 1 / (min* 1.72m^2)$	270(30.8)	253(34.3)	7((	
$GFK, mL/(min^{-1}.73m^{-1})$	$83./9 \pm 19.86$	$83.43 \pm 20.33$	./66	
Platelet count, $10^{3}/\mu L$	$244.61 \pm 62.58$	$42.71 \pm 65.00$	.624	
Neutrophil count, $10^3/\mu L$	$4.22 \pm 1.50$	$4.22 \pm 1.58$	.943	
Lymphocyte count, $10^{3}/\mu$ L	$2.24 \pm 3.97$	$1.98 \pm 1.44$	.147	
Monocyte count, $10^3/\mu L$	$0.59 \pm 0.24$	$0.60 \pm 0.19$	.912	
SII, $\times 10^3$	$566.78 \pm 343.50$	$607.18 \pm 417.46$	.082	
NLR	$2.33 \pm 1.25$	$2.48 \pm 1.32$	.044 <sup>a</sup>	
PLR	$133.21 \pm 53.90$	$141.94 \pm 66.76$	.018 <sup>a</sup>	
LMR				
	$3.73 \pm 1.88$	$3.49 \pm 1.60$	.022ª	

Values are mean  $\pm$  SD or n (%). For categorical variables, *P* values were analyzed by chi-square tests. For continuous variables, *P* values were analyzed by *t* test. All of the continuous variables were exhibited by mean and SD. Abbreviations: BMI, body mass index; ED, erectile dysfunction; GFR, glomerular filtration rate; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PIR, poverty impact ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammatory index; SIRI, systemic inflammation response index. <sup>a</sup>Statistical difference.

Table 4. Prevalence ratios of prevalent erectile dysfunction by inflammatory biomarkers after propensity score matching, National Health and Nutrition Examination Survey 2001-2004.

	Model 1 <sup>a</sup>		Model 2 <sup>b</sup>		Model 3 <sup>c</sup>	
	aOR (95% CI)	Р	aOR (95% CI)	Р	aOR (95% CI)	Р
SII	1.00 (1.00, 1.00)	.131	1.00 (1.00, 1.00)	.125	1.00 (1.00, 1.00)	.102
NLR	1.10 (1.00, 1.21)	.049 <sup>d</sup>	1.10 (1.00, 1.22)	.044 <sup>d</sup>	1.11 (1.01, 1.23)	.034 <sup>d</sup>
PLR	1.00 (1.00, 1.00)	.038 <sup>d</sup>	1.00 (1.00, 1.00)	.040 <sup>d</sup>	1.00 (1.00, 1.00)	.035 <sup>d</sup>
LMR	0.91 (0.84, 0.97)	.010 <sup>d</sup>	0.90 (0.83, 0.97)	.008 <sup>d</sup>	0.90 (0.83, 0.97)	.007 <sup>d</sup>
SIRI	$21.03(0.01, 3.24 \times 10^6)$	.481	22.63 $(0.01, 4.51 \times 10^6)$	.477	$25.79(0.01, 7.14 \times 10^6)$	.472

Abbreviations: aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-tolymphocyte ratio; PIR, poverty impact ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammatory index; SIRI, systemic inflammation response index. <sup>a</sup>Model 1 is unadjusted. <sup>b</sup>Model 2 adjusted for age, race, BMI, smoking, education, and PIR. <sup>c</sup>Model 3 adjusted for model 2 covariates and for hypertension, diabetes, and glomerular filtration rate. <sup>d</sup>Statistical difference.



Adjusted to:Age=65 Race=3 smoke=1 EDU=3 PIR=2 vigorous\_activity=2 moderate\_activity=2 HBP=2 DM=2 GFR=87.51

Figure 4. The dose-response analysis of inflammatory biomarkers and erectile dysfunction after propensity score matching.



Erectile dysfunction

Figure 5. The potential mechanism of action related to inflammatory biomarkers and erectile dysfunction.

with ED and may contribute to ED prevention. However, the evidence supporting this recommendation is still limited, and the mechanisms underlying the relationship between NLR, PLR, or LMR and ED have not been fully studied. Therefore, more comprehensive mechanical studies are essential to figure out the specific relationship of inflammatory biomarkers with ED.

Many factors have been reported to be associated with ED. For example, a cross-sectional research suggested that higher triglyceride-glucose (TyG) index was related to a higher prevalence of ED.<sup>30</sup> However, Compared with biochemical tests, routine blood tests are more convenient and less costly. Therefore, the early warning role of inflammatory indexes for ED will have a broad clinical application.

Our study has some limitations. First, this was a crosssectional study, so the ability to prove causality was not developed. Second, some sexual function rating scales should be used to investigate the erectile function of participants. Third, although PSM can adjust for the effects of confounding factors, it still has drawbacks such as model dependence and bias. Therefore, more carefully designed prospective studies and multicenter studies are necessary to explore the relationship between inflammatory biomarkers and ED.

#### Conclusion

NLR has predictive value as a novel, convenient, and inexpensive marker of inflammation for identifying ED. Therefore, this biomarker can be considered in the clinical setting as a method for ED prevention or early intervention.

#### Author contributions

Conceptualization: C.L. Data curation: Y.G. Formal analysis: C.L., J.J. Funding acquisition: C.S. Supervision: C.S., M.C. Writing - review & editing: all authors.

# Funding

This study was supported by the National Natural Science Foundation of China (No. 81871157).

# **Conflict of interest**

The authors have no conflicts of interest to declare.

### Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

# References

- 1. Shamloul RH. Ghanem. Erectile dysfunction. Lancet. 2013; 12(381):153-165.
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641.
- Nguyen HMT, Gabrielson AT, Hellstrom WJG. Erectile dysfunction in young men-a review of the prevalence and risk factors. Sex Med Rev. 2017;5(4):508–520.
- Kaya-Sezginer E, Gur S. The inflammation network in the pathogenesis of erectile dysfunction: attractive potential therapeutic targets. *Curr Pharm Des.* 2020;26(32):3955–3972.
- Giugliano F, Esposito K, Di Palo C, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. *J Endocrinol Investig.* 2004;27(7): 665–669.
- Chiurlia E, D'Amico R, Ratti C, et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46(8):1503–1506.
- Li H, Qi T, Huang ZS, et al. Relationship between gut microbiota and type 2 diabetic erectile dysfunction in Sprague-Dawley rats. *J Huazhong Univ Sci Technolog Med Sci.* 2017;37(4):523–530.
- Hayward MD, Jones BK, Saparov A, et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. *BMC Physiol*. 2007;7(1):13.
- Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. review article. *Ann Hepatol.* 2021;22:100249.
- Li P, Li H, Ding S, Zhou J. NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma. *Am* J Transl Res. 2022;14(5):3017–3027.
- Mandaliya H, Jones M, Oldmeadow C, Nordman IIC. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). *Transl Lung Cancer Res.* 2019;8(6):886–894.
- 12. Jin Z, Wu Q, Chen S, et al. The associations of two novel inflammation indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: a ten-year follow-up study in 85,154 individuals. J Inflamm Res. 2021;14:131–140.
- Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2): 151–157.
- Hu Y, Niu X, Wang G, Huang J, Liu M, Peng B. Chronic prostatitis/chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model. *Andrology*. 2016;4(6):1209–1216.
- Araña Rosaínz M de J, Ojeda MO, Acosta JR, et al. Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. *J Sex Med*. 2011;8(7):2017–2030.

- Corona G, Mannucci E, Schulman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. *Eur Urol.* 2006;50(3):595–604. discussion 604.
- 17. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. *Eur Heart J*. 2006;27(22): 2640–2648.
- Fujita N, Hatakeyama S, Momota M, et al. Relationships of lowgrade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis. *Andrology*. 2022;10(8): 1548–1555.
- Ventimiglia E, Cazzaniga W, Pederzoli F, et al. The role of neutrophil-to-lymphocyte ratio in men with erectile dysfunctionpreliminary findings of a real-life cross-sectional study. *Andrology*. 2018;6(4):559–563.
- Liao Z, Tang Y, Li X, et al. The relationship between hematologic parameters and erectile dysfunction. Sex Med. 2021;9(4): 100401–100409.
- 21. Zhang Y, Feng X, Wu X, et al. A systematic review and metaanalysis of the relationship between erectile dysfunction and the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. *Andrologia*. 2022;54:e14337.
- 22. Demirci A, Ozgur BC. The effect of using tadalafil 5 mg/day on neutrophil-lymphocyte and platelet-lymphocyte ratios in mild-medium and severe erectile dysfunction patients; and comparison of clinical response. *Andrologia*. 2019;51(9):e13347.
- Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets*. 2015;26(7):680–681.
- Hu Q, Mao W, Wu T, et al. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients. *Front Oncol.* 2021;11:736640.
- 25. Soufli I, Hablal A, Bessaad S, et al. Nitric oxide, neutrophil/lymphocyte, and platelet/lymphocyte ratios as promising inflammatory biomarkers in complicated Crohn's disease: outcomes of corticosteroids and anti-TNF-alpha therapies. *Inflammation*. 2023;46(3):1091–1105.
- 26. Kriplani A, Pandit S, Chawla A, et al. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) in predicting systemic inflammatory response syndrome (SIRS) and sepsis after percutaneous nephrolithotomy (PNL). Urolithiasis. 2022;50(3):341–348.
- Akbas A, Gulpinar MT, Sancak EB, et al. The relationship between platelet-lymphocyte ratio and severity of erectile dysfunction. *Kaohsiung J Med Sci.* 2016;32(2):91–95.
- Li A, Mu X, He K, et al. Prognostic value of lymphocyteto-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. *Future* Oncol. 2020;16(30):2433–2444.
- Huang Q, Wu H, Wo M, Ma J, Song Y, Fei X. Clinical and predictive significance of plasma fibrinogen concentrations combined monocyte-lymphocyte ratio in patients with diabetic retinopathy. *Int J Med Sci.* 2021;18(6):1390–1398.
- 30. Li L, Yao H, Dai W, et al. A higher TyG index is related with a higher prevalence of erectile dysfunction in males between the ages 20-70 in the United States, according to a cross-sectional research. *Front Endocrinol (Lausanne)*. 2022;13:988257.